Abstract. Schistosomal myeloradiculopathy (SMR) is the most severe and disabling form of schistosomiasis. The diagnosis is based on clinical, laboratory, and image data. Vestibular-evoked myogenic potential (VEMP) is a neurophysiologic test that assesses the vestibulospinal pathway through acoustic or galvanic stimuli. The aim of this study was to evaluate cervical spinal abnormalities in patients with SMR. Fifty-two subjects were evaluated, of whom 29 had SMR and 30 did not (normal control). Normal VEMP was observed in all volunteers without SMR. Abnormal VEMP was recorded in 34% of the group with SMR. After treatment, abnormal VEMP was found in 80% of those with persistent neurologic abnormalities. VEMP is a functional test, and the alteration may precede image abnormalities. This procedure may be useful for early diagnosis of schistosomal cervical spinal cord involvement.
INTRODUCTION
Vestibular-evoked myogenic potential (VEMP) is a test that assesses the vestibulospinal pathway, studying the integrity of the brainstem vestibular nuclei and then to the sternocleidomastoid (SCM) muscle through the upper cervical segments and the accessory nerve. 1 The evoked myogenic response is captured with superficial electrodes in the SCM muscle as a biphasic positive-negative wave-form (P13-N23). Damage to any of the structures related to the VEMP pathway results in abnormalities of this potential. [1] [2] [3] VEMP is a simple, inexpensive, rapid and well-tolerated test, easily performed in a laboratory equipped for recording evoked potentials. 4, 5 The importance of VEMP to evaluate the cervical vestibulospinal pathway has been acknowledged. [6] [7] [8] Schistosomal myeloradiculopathy (SMR) is the most severe and disabling ectopic form of Schistosoma mansoni infection. 9, 10 In Brazil, S. mansoni infection affects 4-5 million people. [9] [10] [11] [12] Although schistosomiasis is likely to be responsible for a significant number of cases of myelopathy of unidentified etiology in endemic areas, the prevalence of SMR is unknown. [11] [12] [13] [14] [15] [16] Cervical spinal cord abnormalities, although not as frequent, have been reported in SMR. 17 VEMP may provide useful information about functional cervical spinal cord abnormalities, allowing the detection of early and silent lesions not shown by neuroimaging. This study aims to evaluate subclinical cervical abnormalities in the vestibulospinal pathway in subjects with SMR.
MATERIALS AND METHODS
Patients. Fifty-nine subjects, of whom 30 had no S. mansoni infection (control group) and 29 had SMR, were selected for this study. In the control group, 13 subjects (43%) were men; ages ranged from 23 to 65 years (mean ± SD, 32 ± 10.5 years; median, 31.5 years). Controls were referred to our outpatient clinic for evaluation and treatment of different infectious diseases such as intestinal nematodes and bacterial or viral infections. All 29 patients with SMR were consecutively admitted to the hospital from 2005 to 2007. Twenty-three patients (79%) were men; ages ranged from 27 to 55 years (mean ± SD, 37 ± 6.6 years; median, 36 years). SMR was defined according to the following criteria: evidence of low thoracic/upper lumbar spinal cord lesion, demonstration of exposure to schistosomal infection by microscopic or serologic technique, and exclusion of other causes of transverse myelitis. [9] [10] [11] [12] [13] All patients lived in an area in which schistosomiasis was endemic and had frequent contact with stream water. No patient presented with clinical or laboratory evidence of acute schistosomiasis.
Study protocol. The study was reviewed and approved by the Ethical Committee of the Federal University of Minas Gerais, Brazil. Written informed consent was obtained from all participants according to the Declaration of Helsinki. Patients presenting with lumbar and/or lower limb pain, lower limb weakness, anesthesia, hypoesthesia or paresthesia, bladder and/or intestinal dysfunction, and sexual impotence were considered for the study. Stool examination was performed in three samples obtained on different days, by a sedimentationconcentration method. 9 Rectal biopsy was performed in patients whose stool examination did not show S. mansoni eggs after a routine procedure. 9, 10 Search for IgA and IgG anti-SEA (surface egg antigen) antibodies, using an ELISA technique, was also performed. 9 Complete history, clinical and neurologic examination, blood cell count, prothrombin time, fasting glucose, serum cyanocobalamin, lupus anticoagulant, antinuclear antibodies, VDRL, HBsAg, anti-HBs, anti-HBc, IgM anti-CMV, IgM anti-HSV, anti-HTLV-1/2, and anti-HIV, and magnetic resonance imaging (MRI) were performed to exclude other causes of transverse myelitis. All patients had abdominal ultrasound examination to evaluate the presence of periportal fibrosis. 9 Biochemistry and cytomorphologic examinations of cerebrospinal fluid obtained by lumbar puncture were also performed. 15 MRI studies were performed on a Magnetom Impact Expert Superconducting 1.0-T magnetic system (Siemens, Erlangen, Germany). Scans were obtained in sagittal and axial projections with repetition time (TR) of 500-700 ms and echo time (TE) of 12-15 ms for T1-weighted images. The longer TR/TE (T2-weighted) images were acquired with TRs of 2,000-5,000 ms and TEs of 60-112 ms. T1 sequences were also obtained after intravenous administration of gadopentetate dimeglumine contrast material (gadolinium, 0.1 mmol/kg body weight). Slice thickness was 2-5 mm.
Patients were treated with oral praziquantel (50 mg/kg, single dose) and received intravenous methylprednisolone (15 mg/ kg/day, maximum dose of 1 g/day) for 5 days, followed by oral prednisone (1 mg/kg/day) for 6 months.
Clinical and laboratory examinations were performed at admission and at 6 months of treatment. The level of medullary lesion was studied. The same neurologist did the pre-and post-treatment neurologic evaluations.
Outcome was defined as 1) full recovery when the patient presented complete improvement of his neurologic status; 2) partial recovery when the patient remained with deficits that did not interfere with daily activities (paresthesia, urinary dysfunction, lower limbs weakness, partial erectile dysfunction); and 3) no recovery when no change in the clinical picture was observed after treatment.
The inclusion criteria were, in the control group, subjects without otoneurologic complaints, and in the SMR group, subjects with confirmed diagnosis of SMR. The exclusion criteria for both groups were malformation of pinna and external auditory canal and limitation of neck rotation movement.
VEMP was performed in all patients with SMR 6 months after completion of treatment. The analysis of the VEMP results was conducted in a masked fashion; the examiner was unaware of the treatment outcome.
The normal VEMP response generated the biphasic morphology in a positive-negative wave form at 13 and 23 ms (P13-N23). 2, 18 The abnormal VEMP patterns were "P13-N23 latency prolongation" or "no response." The measured parameters were the peak latency (in ms) of the two early waves P13-N23 and the peak to peak amplitude of the P13-N23 waves with the asymmetry amplitude index. [1] [2] [3] [4] [5] [6] [7] 18 The most important parameters considered in VEMP analysis are P13-N23 latency and amplitude. However, amplitude may vary according to age, 18 muscle strength, 19 and cochlear diseases. 20, 21 Despite having these variables controlled herein, possible bias related to the amplitude discouraged its consideration as a parameter for defining abnormalities in neural conduction. This index compares the effect of muscle tone from one side to the other and is calculated by the inter-aural difference in amplitude of the response, measured by the mean response of each patient. [4] [5] [6] [7] [8] The asymmetry index varies between studies and is considered non-significant when the difference between muscle contractions is < 34.0-47.4%, after the calculation of the equations.
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The electromyographic (EMG) activity was recorded from the upper half of the SCM muscle using surface electrodes, with a reference on the upper sternum and a ground electrode on the forehead. During each recording session, in seated position, the subject was instructed to rotate the head toward the contralateral side of the tested ear to keep the SCM muscle under tension. 19 The acoustic stimuli were short tone bursts (1 kHz, 118 dBHL, rise-fall 1 ms, and plateau 2 ms).
The stimulation rate was 5 Hz, and the analysis time for each response was 60 ms; 200 responses were averaged for each run. The EMG signals were amplified and band-pass filtered between 10 and 1,500 Hz (Bio-logic Program, Natus Medical Inc., San Carlos, CA ). The responses were recorded twice in both sides to confirm replication. 4 The tests were conducted in silence and in an acoustically treated environment. After the recording of all individuals, the analysis of results was masked to eliminate bias (patients and controls received numbers and the examiner ignored which group the subject belonged to).
Statistical analysis. Proportions were compared using the c 2 or Fisher exact test as needed; differences between means were assessed using Student t or analysis of variance (ANOVA)/ Scheffé tests. Linear trend analysis was carried out to identify a possible dose-response association between VEMP abnormalities and patient clinical recovery. In all statistical procedures, P < 0.05 was considered significant.
RESULTS
Ultrasound showed no periportal liver fibrosis in the SMR group. The tests performed to diagnose other diseases resulted negative.
Baseline characteristics of the patients are depicted in Table 1 . Clinical and MRI findings of all patients with SMR before and after treatment are presented in Table 2 .
Responsive VEMP was found in all controls, and the mean values were latency of the P13 = 13.66 ± 0.52 ms and latency of the N23 = 23.23 ± 0.95 ms; the asymmetry rating regarding amplitude = 26.36%.
Normal VEMP response was recorded in 19 subjects of the study group (SMR). The mean values were latency of the P13 = 13.8 ± 0.6 ms, and the latency of the N23 = 23.7 ± 0.38 ms; the asymmetry rating regarding amplitude = 30.17%.
Abnormal VEMP was recorded in 10/29 patients with myeloradiculopathy (34%), with no response in 4 of 10 (40%). Among the six responsive, there was prolongation of P13-N23. The mean values were latency of the P13 = 14.60 ± 0.09 ms, and latency of the N23 = 25.3 ± 0.51 ms; the asymmetry rating regarding amplitude = 29.41%. There was higher prolongation of both latencies P13/N23 , when the means of the six responsive patients were compared with normal controls ( N = 30) and patients with myeloradiculopathy without VEMP alterations ( N = 19; P < 0.05, ANOVA/Scheffé). VEMP response was correlated to neurologic abnormalities after treatment, and abnormal VEMP was found in 80% of those with neurologic abnormality ( P < 0.05; Table 3 ).
Trend analysis showed a statistically significant linear tendency ( Figure 1 ) . The relative odds for VEMP abnormalities were 3 and 18 times higher for "partial recovery" and "no recovery," respectively, compared with "full recovery" (c 2 trend = 7.48; P < 0.006).
DISCUSSION
The accuracy of VEMP to define the absence of functional disease in the cervical spinal cord related to the vestibulospinal tract pathway was guaranteed by the evaluation of the normal control group. [1] [2] [3] [4] [5] [6] [7] [8] [18] [19] [20] [21] Previous studies showed that age and sex did not have any influence on VEMP latency responses 18,20 but did influence age-related changes of P13-N23 amplitudes. 19 In this study, the latter had no influence on our results.
VEMP has shown to be of value in diagnosing neuronal conduction abnormalities of the vestibulospinal pathway in multiple sclerosis, HTLV-1-associated myelopathy, and medullary trauma. [6] [7] [8] However, it had not been studied in SMR. In our patients with SMR, VEMP results varied according to the neurologic status of the patients. Possibly, the SMR patients with neurologic alterations and abnormal VEMP would have lesions in the cervical spinal cord, which were not shown by neuroimaging. [5] [6] [7] Cervical spinal cord abnormalities, although not as frequent, have been reported in SMR. 17 Therefore, this electrophysiologic test may be useful to detect alterations that are not observed using imaging techniques. It may also be important in the evaluation of the extent of spinal cord involvement and the response to SMR treatment.
To our knowledge, there has been no investigation of the cervical spinal cord in patients with schistosomiasis and spinal cord involvement elsewhere (lumbar or thoracic areas) or brain tumor. This technique should certainly be added to the protocol of investigation in forthcoming studies. It is also of interest in SMR to check the integrity of the spinal cord using galvanic methods with electrodes recording impulses in muscles of the legs, because this would permit the evaluation of the whole extent of the spinal cord. 22 One limitation of our study is, of course, the absence of histologic evidence of spinal cord disease in patients who presented abnormal or no response to VEMP. Biopsy of the spinal cord in such cases is out of question and would not be proposed by the investigators nor accepted by Ethical Boards. Therefore, we must study the spinal cord of cadavers with spinal cord disease elsewhere to check the concomitant involvement of the cervical spinal cord in those with altered VEMP.
Our patients were examined with VEMP 6 months after treatment with praziquantel and steroids. Because the test performed well (i.e., identified patients with spinal cord alterations, including those with normal neuroimaging), we intend, from now on, to use the test before treatment in patients with different degrees of spinal cord injury to help in diagnosis and in the evaluation of response to treatment.
In conclusion, VEMP, as any other evoked myogenic potential (galvanic, for example), may be used to screen for silent lesions and help in early diagnosis of even subtle spinal cord involvement. For SMR, this test was shown to be useful in diagnosing upper medullary involvement and should be tried in forthcoming studies to evaluate treatment response. 
